MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijrobp.2025.10.029

Медицинская библиотека · International journal of radiation oncology, biology, physics · 2025

Nimotuzumab Plus Image-Guided Radiation Therapy for Elderly Patients with Locally Advanced Cervical Squamous Cell Carcinoma: Interim Analysis of a Prospective Multicenter Phase II Trial.

Qu Ang, Zhuo Yanhong, Zhu Hong, Sun Xiaoge, Gao Yuhua, Cheng Huijun, Zhao Fengju, Song Yipeng, Wen Qinglian, Zhou Xiaohong, Wang Ping, Yang Jialin, Zou Lijuan, Yuan Xiangkun, Wu Dongyue, He Jianli, Zhang Yunyan, Wei Lichun, Liu Zi, Wang Junjie

СтатьяКлиническое исследование II фазыМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

PURPOSE: Elderly patients with locally advanced cervical squamous cell carcinoma (LACSCC) generally have fewer therapeutic choices. Nimotuzumab, as an epidermal growth factor receptor-targeted humanized monoclonal antibody, has low toxicity, and shown antitumor efficacy in cervical cancer in preliminary study. Therefore, we wanted to explore efficacy and safety of nimotuzumab and image-guided radiation therapy for elderly patients with LACSCC.

METHODS AND MATERIALS: This is a prospective, multicenter, open-label, single-arm, and phase II trial. LACSCC patients aged ≥ 65 years not receiving chemotherapy were enrolled. All of the patients received intensity-modulated radiation therapy and image-guided brachytherapy. Nimotuzumab was administration of 200 mg once a week for 6 weeks. Disease-free survival (DFS) is the primary endpoint. Secondary endpoints included overall survival (OS), complete response rate, objective response rate, and safety.

RESULTS

From November 2021 to January 2023, a total of 118 elder patients with stage IB3-IVA were enrolled. The median follow-up was 24 months (95% CI: 21.78, 25.53). The complete response rate was 61.86% (95% CI, 0.53-0.71), objective response rate was 91.53% (95% CI, 0.85-0.96). The 1 year-DFS and 2 year-DFS were 92.42% (95% CI, 85.40-96.14) and 84.61% (95% CI, 75.07-90.72), respectively, the median DFS was 36.99 months (95% CI, NA, NA). The 1 year-OS was 96.19% (95% CI, 90.15-98.55), 2 year-OS was 88.22% (95% CI, 78.87-93.60), the median OS was not reached. The most common grade 3 adverse events included leukopenia (4/30.77%), neutropenia (3/23.08%), lymphopenia (2/15.38%), diarrhea (1/7.69%), and anemia (3/23.08%). No drug-related severe adverse events or deaths were recorded.

CONCLUSIONS

Among elderly LACSCC patients, nimotuzumab plus image-guided radiation therapy and brachytherapy was well tolerated and indicated promising clinical survival benefits. The robustness of efficacy and toxicity results might provide a novel treatment option for this population.

Для цитирования: Qu Ang, Zhuo Yanhong, Zhu Hong, Sun Xiaoge, Gao Yuhua, Cheng Huijun, Zhao Fengju, Song Yipeng, Wen Qinglian, Zhou Xiaohong, Wang Ping, Yang Jialin, Zou Lijuan, Yuan Xiangkun, Wu Dongyue, He Jianli, Zhang Yunyan, Wei Lichun, Liu Zi, Wang Junjie. Nimotuzumab Plus Image-Guided Radiation Therapy for Elderly Patients with Locally Advanced Cervical Squamous Cell Carcinoma: Interim Analysis of a Prospective Multicenter Phase II Trial.. International journal of radiation oncology, biology, physics. 2025. DOI: 10.1016/j.ijrobp.2025.10.029.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.